Center Archives - Healthy News

Meihua International Medical Technologies Co., Ltd. Enters Into Cooperation Agreements with Hainan’s Qionghai City and Hainan Free Trade Port Boao Hope City to Build Technology Park and Medical Research and Development Center

YANGZHOU, China, Feb. 21, 2023 /PRNewswire/ — Meihua International Medical Technologies Co., Ltd. (“MHUA” or the “Company”) (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, today announced the Company, via its subsidiary company Hainan Guoxie Medical Technology Co. (“Hainan Guoxie”), has entered into cooperation agreement (the “Qionghai Agreement”) with Qionghai City of Hainan Province to build technology park project. Hainan Guoxie also entered into cooperation agreement (the “Hope City Agreement”) with Hainan Free Trade Port Boao Hope City (“Hope City”) to build MHUA a medical research and development center in the Hope City.

Pursuant to the Qionghai Agreement, Hainan Guoxie plans to invest in the construction of a medical industrial park in Hainan Province for the will be focused on the development of minimally invasive interventional medical devices, new materials and surgical robotics technologies. Hainan Guoxie and Qionghai City government reached preliminary agreement to bid for the usage of nearly 574,080 sq ft of land around Hope City for the construction of a Contract Development and Manufacturing Organization (CDMO) medical industrial park. The Company anticipates making a more detailed public announcement of the land use right purchase information in about one month’s time.

Pursuant to the Hope City Agreement, the planned MHUA medical R&D center will carry out the research and development of stem cell to human targeted therapies and rehabilitation training projects.

Presently, Hope City is the only special medical parkin China, which was approved by China State Council in 2013 and offers a series of special policies such as “licensed medical treatment, licensed research, licensed operation and licensed international medical technology exchange,” and is a key project for the construction of the Hainan Free Trade Port. At present, there are 20 medical institutions involved in more than 10 projects under construction or planned in the pipeline, with 51 medical academicians forming the expert advisory team. In addition, Hope City has established cooperation with 30 of the top international pharmaceutical and medical devices enterprises, serving as one of the main channels for the importation of innovative products into China. The volume of licensed medicines and medical devices imported has exceeded 200 categories, effectively facilitating the advancement of medical technology, devices and medicine development in China to catch up with the international market.

MHUA’s project is highly valued by the local government of Hope City, who recently paid a special visit to the Company’s headquarters. Mr. Liu Yongjun, chairman of MHUA, commented: “Hainan has many advantageous conditions as China’s national free trade port, which will provide many convenience for MHUA’s products exporting to foreign markets, new product research and development, and taxation, among other things. It is a great honor for us that Qionghai City and Hope City selected the Company as one of the contracted companies to promote medical industry projects locally. MHUA will strive to improve the level of intelligence, information technology, digitalization and innovation, and accelerate the transformation and upgrade of our business, in order to promote the Company’s high-quality development and create sustainable value for our shareholders.”

About Meihua International Medical Technologies Co., Ltd.

Meihua International Medical Technologies is a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China. The Company manufactures and sells Class I disposable medical devices, such as eye drop bottles, medicine bottles and anal bags, and Class II and III disposable medical devices, such as identification tape, gynecological examination kits, inspection kits, surgical kits, medical brushes, medical dressing, masks, disposable infusion pumps, electronic pumps and puncture kits, which products are sold under its own brands and also sourced and distributed from other manufacturers. The Company has received international “CE” certification and ISO 13485 system certification and has also registered with the FDA (registration number: 3006554788) for more than 20 products. The Company has served hospitals, pharmacies, medical institutions and medical equipment companies for over 30 years, providing more than 800 types of products for domestic sales, as well as 120 products which are exported to more than 30 countries internationally across Europe, North America, South America, Asia, Africa and Oceania. For more information, please visit www.meihuamed.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s ability to achieve its goals and strategies, and its ability to fully execute on the planned agreement, the Company’s future business development and plans of future business development, including its ability to successfully develop robotic assisted surgery systems and obtain licensure and certification for such systems, financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions in China, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission (“SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, including under the section entitled “Risk Factors” in its annual report on Form 20-F, as filed with the SEC on July 29, 2022, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Janice Wang
Wealth Financial Services LLC
Phone:
+86 13811768599
+1 628 283 9214
Email: services@wealthfsllc.com

Cision

View original content:https://www.prnewswire.com/news-releases/meihua-international-medical-technologies-co-ltd-enters-into-cooperation-agreements-with-hainans-qionghai-city-and-hainan-free-trade-port-boao-hope-city-to-build-technology-park-and-medical-research-and-development-center-301751576.html

SOURCE Meihua International Medical Technologies Co., Ltd.

FAU, DELRAY MEDICAL CENTER, INSIGHTEC TEAM UP ON GROUNDBREAKING ALZHEIMER’S STUDY

First Individual in Florida Dealt with with Non-invasive Concentrated Ultrasound Technological innovation

BOCA RATON, Fla., Feb. 20, 2023 /PRNewswire/ — Delray Clinical Centre is the 1st clinic in Florida to handle an Alzheimer’s condition client working with non-invasive focused ultrasound technological innovation as component of a groundbreaking analyze currently being carried out in collaboration with Florida Atlantic University’s Institute for Human Overall health and Ailment Intervention (I-Health).

In the Food and drug administration-authorised scientific demo, targeted ultrasound engineering is applied to disrupt the blood-brain barrier in taking part Alzheimer’s patients. Alzheimer’s may possibly be brought on by a buildup of certain proteins in the mind. Specifically guided by magnetic-resonance imaging, ultrasound waves are directed at precise spots of the patient’s mind to build a momentary opening in the blood-mind barrier where by the protein buildup may well be minimized. The Delray Health-related Centre affected individual enrolled in the clinical trial gained the to start with of a few treatment options at the hospital on Feb. 15.

“Delray Medical Center is very pleased and fired up to be a leader in this effort to determine the protection and efficacy of this perhaps revolutionary procedure for Alzheimer’s sufferers,” explained Lloyd Zucker, M.D., FAANS, a board-certified neurosurgeon and health care director of neurosurgery at Delray Professional medical Centre. “The review will aid determine whether or not the use of this non-invasive centered ultrasound technological know-how can lead to cognitive enhancement in people with Alzheimer’s disorder.”

An estimated 6.5 million Us citizens ages 65 and older are dwelling with Alzheimer’s disorder, which is the sixth major result in of death for those age 65 and higher than in the U.S., according to the Alzheimer’s Affiliation. Florida has the second maximum incidence of Alzheimer’s in the state, with an approximated 580,000 conditions.

“By developing the Florida Alzheimer’s Heart of Excellence previous calendar year, Florida Gov. Ron DeSantis has placed Alzheimer’s disease as a precedence health and fitness problem in Florida, which will profit the additional than 580,000 folks now living with Alzheimer’s as very well as their families,” explained FAU President Stacy Volnick. “We are psyched to collaborate with Delray Clinical Heart, Insightec and others on this groundbreaking technology that will generate the upcoming technology of affected person care for Alzheimer’s disease and other neurodegenerative disorders.”

FAU’s Gregg Fields, Ph.D., executive director of I-Overall health and a professor of chemistry and biochemistry in FAU’s Charles E. Schmidt Higher education of Science, is the software director for the undertaking.

“Drug passage as a result of the blood-brain barrier is probably a person of the greatest troubles in neurology,” claimed Fields. “The remedy of the initial client in Florida with the non-invasive centered ultrasound engineering signifies a important progression for opportunity drug shipping and procedure of Alzheimer’s sickness and other neurological issues. In tandem, we are also doing work on non-invasive, blood-based mostly monitoring to decide if treatments are effective.”

The scientific trial, identified as ExAblate Blood-Brain Barrier (BBB) Disruption for the Therapy of Alzheimer’s Sickness, is made to evaluate the protection and efficacy of Insightec’s ExAblate Model 4000 Variety 2. Process as a resource for disrupting the blood-brain barrier in probable Alzheimer’s individuals.

“Insightec is fully commited to operating with our associates to help travel innovation,” mentioned Maurice Ferre, M.D., chairman and CEO from Insightec. “By giving our healthcare technologies to hospitals and universities across the state of Florida, we are building a cross-sector community with advanced abilities to accelerate investigate for opportunity procedure options for brain illnesses.”

The examine, portion of Florida’s Mind Condition initiative, is remaining conducted at up to 8 internet sites in the country. Sufferers who satisfy the specific study requirements obtain a few targeted ultrasound treatment options, two months aside, and will be adopted for 5 years following the closing course of action.

“These days marks a historic milestone in the fight towards Alzheimer’s as we begin trials in Florida working with Insightec’s reducing-edge focused ultrasound technologies,” reported Jonathan Weiss, chairman of the Alzheimer’s Disorder Advisory Committee and vice president of strategic innovation at Insightec. “Thanks to Gov. DeSantis’ visionary leadership, the Florida legislature’s aid, and the unparalleled partnership amongst Florida’s academic powerhouses, well being methods and non-public marketplace, we are happy to launch this pioneering research system aimed at treating and finally acquiring a overcome for Alzheimer’s. This accomplishment alerts a new era in professional medical research, featuring hope to thousands and thousands of people and people impacted by this devastating illness.”

The Insightec know-how has previously been demonstrated to be efficient in managing people with Parkinson’s ailment and important tremor, a neurological ailment that will cause involuntary trembling of the head and fingers, protecting against people with the affliction from doing basic tasks, these types of as ingesting from a glass or tying shoelaces.

“I have used a great deal of my profession doing work and hoping for developments in Alzheimer’s study, so I am very energized for what this suggests for the hundreds of 1000’s of Floridians living with Alzheimer’s and their caregivers,” explained Michelle Branham, Division of Elder Affairs secretary. “Our governor has been a steadfast supporter of the Mind State software and proceeds to champion Alzheimer’s initiatives and increasing budget recommendations to make sure Florida continues to be a leader in analysis, assistance and treatment method. This profitable remedy is a historic and pivotal second for our state and its dedication to a fortified composition to support Alzheimer’s and other dementias. I am extremely happy to be a lover in the Brain Point out Plan.”

To obtain out additional about Delray Healthcare Center’s targeted ultrasound method, take a look at www.delraymedicalctr.com/providers/neurosciences/concentrated-ultrasound.

About Florida Atlantic University:

Florida Atlantic College, established in 1961, formally opened its doors in 1964 as the fifth general public college in Florida. Now, the University serves additional than 30,000 undergraduate and graduate pupils throughout 6 campuses positioned alongside the southeast Florida coastline. In modern years, the College has doubled its analysis expenditures and outpaced its peers in college student achievement costs. By the coexistence of access and excellence, FAU embodies an ground breaking model wherever common accomplishment gaps vanish. FAU is designated a Hispanic-serving establishment, rated as a top community college by U.S. Information & Entire world Report and a Superior Research Action establishment by the Carnegie Basis for the Improvement of Training. For a lot more information, stop by www.fau.edu.

About Delray Health care Middle:

Delray Health care Centre, component of the Palm Beach front Health Community, is a 536-bed acute treatment medical center, spanning 30 acres, employing about 1,700 staff, 700 doctors, serving southern Palm Seashore County for above 40 decades. As each a group medical center and state-specified Amount I Trauma Heart Delray Health care Center provides several specialised services like point out-of-the artwork cardiac and vascular facilities, orthopedics, neurosciences, unexpected emergency treatment, and fat-reduction surgical treatment.

Pinecrest Rehabilitation and Outpatient Healthcare facility at Delray Clinical Center is the only state specified mind and spinal wire harm rehabilitation method in the county by the State of Florida. Delray Medical Heart is also residence to Reasonable Oaks Pavilion, a 53-mattress adult psychiatry device. For more info about our products and services, visit our web-site at www.delraymedicalctr.com.

This information launch was issued on behalf of Newswise(TM). For additional facts, take a look at http://www.newswise.com.

Media Contacts: Gisele Galoustian
Senior Media Relations Director, Analysis and Wellness
[email protected]
Cellular: 561-985-4615

Andrew Lofholm
Communications Supervisor
[email protected]
Mobile: 561-450-0921

Resource Florida Atlantic College

McLaughlin Research Institute plans to establish a clinical research center

Wonderful FALLS — The McLaughlin Analysis Institute for Biomedical Sciences in Good Falls has served a major position in biomedical analysis in Montana for almost 70 decades.

Even though a great deal of their research has concentrated on working with mouse versions as a way to dissect the genetic basis of susceptibility to neurodegenerative diseases, they are on the path in the direction of a a lot more substantial goal, in the hopes that it will provide all types of benefits to the Treasure Condition. That purpose is creating 1 of the nation’s very first rural medical exploration facilities, which will be aimed at expanding clinical investigation in neurodegenerative conditions.

McLaughlin Study Institute Assistant Professor, Tiffany Hensley-McBain mentioned, “There are hundreds of scientific trials enrolling in Alzheimer’s disease correct now, and zero of them are recruiting in Montana. In point, usually, only eight studies on Alzheimer’s disorder have ever enrolled a Montanan.”

McLaughlin Investigate Institute claims the want for medical research growth in the state of Montana has grow to be much more important than at any time. They noted that Montana has regularly rated in the bottom 10{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} when it comes to participation and illustration in medical research nationwide.

They also mentioned that Montana has the sixth oldest population ratio in the nation. A little above 19 percent of our overall inhabitants is around the age of 65.

McLaughlin Investigate Institute says owing to the threat of neurodegenerative ailments growing with age, endorsing the enlargement of science and medicine by way of medical research that targets improvements in prognosis, cure, and avoidance of neurodegenerative diseases is a priority worry.

Clinical Exploration Coordinator, Rebecca Brown stated, “Scientific trials are at the coronary heart of all health-related developments. They are a system by which folks have obtain to the newest and ideal therapy. They also have the opportunity to deliver a whole lot of expertise to the neighborhood, and if we can carry in some clinical investigation on dementia and Alzheimer’s condition, I actually imagine that we can deliver a terrific profit to our state.

In an energy to raise the inclusion and expansion of medical investigation in Montana, McLaughlin Investigation Institute has introduced a registry of possible members for clinical investigation. This registry is open up to any older people of any age or prognosis. The function is to get a checklist of likely individuals for long term investigate research. The registry is referred to as “HERO” (Assisting Grow Investigation Alternatives).

How does the HERO Registry operate:

Your get hold of information is securely saved in a HIPAA – compliant database.
Minimum details is gathered.
Persons may perhaps be contacted if qualified for a examine, and there is no obligation to take part.
Any individual of any age and wellbeing position is encouraged to register

To understand extra, speak to McLaughlin Exploration Institute for Biomedical Science at 406-452-6208, or by clicking in this article.

TRENDING

Adhere to KRTV

Naval Medical Research Center Uses Genome Sequencing for Variants

&#13

&#13
Suggested Written content:&#13

&#13
&#13
Research and Innovation | Coronavirus & the MHS Response | Coronavirus&#13
&#13
&#13

Editor’s observe: This is the fifth posting in a 6-aspect sequence that highlights the do the job of specialists and researchers in Navy Well being Method laboratories who worked to recognize COVID-19 variants using distinctive sequencing know-how.

The Naval Health-related Exploration Center’s Biological Protection Investigation Directorate has sequenced above 6,700 samples and offered assist to important shipboard and navy education populations to recognize COVID-19 variants. Particular fleet assets supported with viral genome sequencing by NMRC involve the USS Theodore Roosevelt and eight other ships. It also consists of army therapy facilities, the fleet, and the U.S. Army, U.S. Air Force, U.S. Navy, and U.S. Marine Corps units, with samples originating in the United States and from four continents.

“Becoming in a position to offer in depth information relating to the variants will allow for up-to-day information to the fleet and Marine drive, as perfectly as other expert services,” claimed U.S. Navy Capt. William Deniston, commander of Naval Medical Research Middle. “This information aids advise leadership on the most present threats to the armed forces.”

The facts presented on samples from Camp Lemonnier, a U.S. naval foundation in Djibouti, Africa, aided provide crucial details for stakeholders in U.S. Africa Command and the West African region, by giving surveillance of circulating variants in U.S. forces in an below-sampled region. The SARS-CoV-2 genome sequences developed at NMRC had been the to start with released viral sequences from Djibouti and resulted in identification of unusual mutations.

Headquartered at Fort Detrick, Maryland, the NMRC-BDRD also performed an instrumental purpose in the COVID-19 outbreak response, coordinating SARS-CoV-2 sample receiving and sharing amongst labs in the Countrywide Funds Region. NMRC’s efforts offered crucial support for sequencing and viral isolation to the Division of Protection and Armed forces Overall health Technique, as perfectly as instruction to associate laboratories on SARS-CoV-2 protocols and bioinformatics examination.

“NMRC’s BDRD is uniquely qualified to conduct the deep sequencing essential to do this work. The incredible scientists we have at NMRC are the very best in the business enterprise,” said Deniston.

Cardiovascular Research Foundation Announces Clinical Trials Center Executive Director

December 30, 2022 — The Cardiovascular Exploration Foundation (CRF) lately declared that Alexandra Popma, MD, has joined the group as Executive Director of the CRF Medical Trials Heart (CTC). A distinguished researcher with more than 20 a long time of encounter, Popma will come to CRF from The Baim Institute for Clinical Exploration, a whole-support nonprofit educational analysis group in Boston, exactly where she served as Chief Functioning Officer, according to the CRF assertion on the appointment. As Govt Director of the CRF Medical Trials Center (CTC), she assumes accountability for the strategic route, administration, and operational areas of the CTC, doing the job intently with all CTC departments to guarantee that the division carries on to produce excellent study products and services.

Prior to joining CRF, Popma was also the Director of the Cardiovascular Imaging Core Laboratory at Harvard Clinical College Physicians at Beth Israel Deaconess Professional medical Centre in Boston. Below her management, the main laboratory made revolutionary techniques for the analyses of cardiovascular imaging to superior recognize the outcomes of people undergoing new device remedy. She acquired her clinical degree from University del Rosario in Bogotá, Colombia.

“I am quite psyched to sign up for the CRF Clinical Trials Centre,” explained Dr. Popma, adding, “CRF is an organization with an impeccable track record for innovation in cardiovascular drugs and client care…working closely with CRF’s environment-renowned medical professional management, I hope to bolster the CTC’s knowledge in clinical demo design and style and growth.”

CRF management supplied the pursuing on the addition of Popma to the CRF crew:

“We are delighted to welcome Alexandra to CRF,” claimed Juan Granada, MD, CRF’s President and Main Govt Officer. He extra, “Dr. Popma’s unique track record and encounter will strengthen CRF’s investigate group and our abilities to take a look at the scientific overall performance of emerging cardiovascular technologies. She is a widely highly regarded medical professional whose management and experience will develop our latest research abilities and providers to our sponsors.”

“Alexandra Popma is a impressive leader and is uniquely capable to presume the part as Government Director of the CTC,” stated Martin B. Leon, MD, CRF Founder and Chairman Emeritus. “She has the expertise, knowledge, decisiveness, arms-on motivation to detail, and advancement-oriented persona to aid guide the CTC to unparalleled heights in the potential. We are so lucky to have Alexandra be a part of CRF in this very important management place,” included Leon.

The Cardiovascular Investigation Foundation (CRF) is a nonprofit corporation specializing in interventional cardiology innovation, exploration, and education. CRF is committed to assisting medical doctors make improvements to survival and top quality of lifestyle for folks struggling from heart and vascular disease. The corporation notes that it has aided speed up professional medical breakthroughs and educated medical practitioners on the most recent treatments for coronary heart sickness for about 30 a long time. CRF’s centers of excellence include things like the CRF Skirball Center for Innovation, CRF Scientific Trials Heart, CRF Heart for Education, CRF Digital, TCTMD, and Structural Heart: The Journal of the Coronary heart Group.

Transcatheter Cardiovascular Therapeutics (TCT) is the yearly scientific symposium of CRF and the leading educational conference specializing in interventional cardiovascular medicine. TCT attributes main healthcare research breakthroughs and gathers primary scientists and clinicians from about the world to existing and focus on the latest proof-based mostly analysis in the subject.

For far more information: www.crf.org

For linked coverage of TCT: https://www.dicardiology.com/channel/tct

Naval Medical Research Center Begins Phase 1 Testing of Diarrhea Vaccine

SILVER SPRING, Md. — Scientists with Naval Professional medical Analysis Centre (NMRC)’s Enteric Illnesses Department have partnered with the Nationwide Institute of Health’s National Institute of Allergy and Infectious Diseases to start off phase 1 tests of a new Campylobacter jejuni vaccine, NMRC introduced in a Dec. 19 release.

Campylobacter jejuni, a foodborne pathogen, is one particular of the most widespread results in of diarrheal health issues in the U.S. and abroad, and can influence readiness of deployed or touring services associates.

Stage 1 tests, at the moment underway at Cincinnati Children’s Healthcare facility Clinical Center, focuses on the security and finest signifies of Campylobacter vaccine shipping. Scientists will vaccinate 60 patients in total as section of Phase 1 tests. This very first phase of screening is predicted to proceed by the conclude of 2023.

Stage 2 tests will include vaccinating groups of grown ups with a dose of the vaccine identified in stage 1, to ascertain its effectiveness in protecting against Campylobacter. NMRC scientists anticipate to get started period 2 screening by 2025 at the earliest, based on funding and the facilities out there.

Diarrhea is a regularly transpiring disease throughout armed service functions, even with modern preventive medicine efforts. The affect of serious diarrhea can be debilitating and impair a assistance member’s capacity to do their position. Acute diarrheal disease for the duration of deployment is normally accountable for reduction of obligation times, negatively has an effect on mission readiness and may well be lethal in the worst situations.

“With genuinely infectious diarrhea, you get cramping, and if you have cramps, you simply cannot definitely function,” mentioned Dr. Frederic Poly, head of NMRC’s Enteric Illnesses Section, who has been associated with the venture since 2005. “You can acquire a fever you’re going to get dehydrated and you’re heading to get rid of cognitive perception. These are all indications that will negatively influence how you function.”

Next recovery from original an infection and bouts of diarrhea, people today can nonetheless working experience very long-term results of infection.

“With Campylobacter, there’s potential downstream effects, like irritable bowel syndrome or Guillain-Barré syndrome, which can lead to respiratory and neurological concerns,” observed Lt. Yuliya Johnson, a microbiologist with NMRC. “It does not materialize to every person, but there is still an linked threat we hope to mitigate by establishing a vaccine.”

According to Poly, this vaccine will be the initial created for use against Campylobacter, and if successful, has the prospective to profit civilian and pediatric populations as nicely. Vaccination at a youthful age can control developmental problems brought about by diarrhea that may well otherwise have an effect on physical and psychological progress in kids.

Poly, NMRC’s most new senior civilian of the quarter for science, prospects the NMRC Enteric Disorders Department. The division, composed of 23 full time microbiologists, molecular biologists, biochemists and immunologists, researches treatment plans for the prevention of infectious bacterial diarrhea.

This past 12 months, the section concluded advancement and medical evaluation of a prophylactic against a further navy suitable enteric pathogen, ETEC (enterotoxigenic E. coli). The enteric disorders lab is also working on the improvement of an oral prophylactic to protect against an infection from several other intestinal pathogens.

NMRC and its instructions are engaged in a wide spectrum of exercise from simple science in the laboratory to area scientific studies in austere and remote parts of the environment to investigations in operational environments. In help of the Navy, Maritime Corps and joint U.S. warfighters, researchers review infectious diseases, organic warfare detection and protection, battle casualty care, environmental health and fitness fears, aerospace and undersea drugs, professional medical modeling, simulation, operational mission aid, epidemiology and behavioral sciences.